

ENANTA PHARMACEUTICALS INC  
Form 8-K  
August 21, 2013

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

WASHINGTON, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF THE**  
**SECURITIES EXCHANGE ACT OF 1934**

**Date of Report (Date of earliest event reported): August 18, 2013**

**ENANTA PHARMACEUTICALS, INC.**

(Exact Name of Registrant as Specified in Charter)

**Delaware**  
(State or Other Jurisdiction  
  
of Incorporation)

**001-35839**  
(Commission  
  
File Number)

**04-3205099**  
(IRS Employer  
  
Identification No.)

Edgar Filing: ENANTA PHARMACEUTICALS INC - Form 8-K

**500 Arsenal Street**

**Watertown, MA 02472**

**(Address of Principal Executive Offices) (Zip Code)**

**(617) 607-0800**

**(Registrant's telephone number, including area code)**

**Not Applicable**

**(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 40.13e-4(c))

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On August 18, 2013, Gregory L. Verdine submitted his resignation as a director of Enanta in light of his increased commitments as the newly elected CEO of Warp Drive Bio. In addition to his service on Enanta's Board of Directors, Dr. Verdine served as a member of the Board's Compensation Committee and its Nominating and Corporate Governance Committee. Dr. Verdine's resignation, which was effective immediately, is not the result of any disagreement with Enanta on any matter relating to its operations, policies or practices.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ENANTA PHARMACEUTICALS, INC.**

Dated: August 21, 2013

By: /s/ Jay R. Luly, Ph.D.  
Jay R. Luly, Ph.D.  
President and Chief Executive Officer